Esperion Therapeutics (NASDAQ:ESPR) General Counsel Sells $23,917.39 in Stock

Esperion Therapeutics, Inc. (NASDAQ:ESPR) General Counsel Benjamin Looker sold 6,517 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total value of $23,917.39. Following the completion of the sale, the general counsel directly owned 385,905 shares of the company’s stock, valued at approximately $1,416,271.35. This trade represents a 1.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Esperion Therapeutics Stock Performance

NASDAQ:ESPR traded up $0.15 during trading hours on Thursday, hitting $3.80. 4,097,221 shares of the company’s stock traded hands, compared to its average volume of 5,496,053. The stock’s fifty day moving average price is $3.16 and its two-hundred day moving average price is $2.28. The firm has a market cap of $908.44 million, a P/E ratio of -7.60 and a beta of 1.01. Esperion Therapeutics, Inc. has a twelve month low of $0.69 and a twelve month high of $4.13.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.07). The business had revenue of $87.31 million during the quarter, compared to analysts’ expectations of $78.33 million. On average, equities research analysts predict that Esperion Therapeutics, Inc. will post -0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ESPR. Cantor Fitzgerald reiterated an “overweight” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Friday, September 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Finally, Citigroup restated a “market outperform” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Esperion Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $7.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company boosted its holdings in Esperion Therapeutics by 7.4% in the second quarter. The Manufacturers Life Insurance Company now owns 72,705 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 4,979 shares in the last quarter. CWM LLC raised its holdings in Esperion Therapeutics by 46.5% during the third quarter. CWM LLC now owns 19,674 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 6,249 shares in the last quarter. DHJJ Financial Advisors Ltd. lifted its position in shares of Esperion Therapeutics by 209.2% in the third quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 6,380 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Esperion Therapeutics by 54.1% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 23,916 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 8,394 shares in the last quarter. Finally, North Star Investment Management Corp. boosted its stake in shares of Esperion Therapeutics by 40.0% during the 3rd quarter. North Star Investment Management Corp. now owns 35,000 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 10,000 shares in the last quarter. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.